BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220929
DTSTAMP:20260516T033510
CREATED:20220531T070301Z
LAST-MODIFIED:20220531T070301Z
UID:34307-1664150400-1664409599@www.pharmajournalist.com
SUMMARY:4th RAS-Targeted Drug Development Summit
DESCRIPTION:For decades\, RAS has existed as an elusive therapeutic target\, and drugging this high-value oncogene was deemed impossible. Despite this\, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is\, in fact\, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation. \nThe 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before\, we will unite 300+ experts to showcase 3-days of exclusive\, never shared before data as we delve into accelerating discovery and emerging strategies\, optimizing translation and pre-clinical development\, and advancing the landscape of clinical trials for combinations and monotherapies. \nWith mounting success in targeted RAS drugs\, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need.  Through novel data\, expert insight\, and exclusive discussions with global leaders\, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C\, G12D\, and G12V. Continuing to advance valuable combination therapies into the clinic\, and finally\, crack resistance to RAS targeted therapeutics. \nAccess the official agenda for more information. \nEarly-bird & team discounts available – Secure your place today.
URL:https://www.pharmajournalist.com/event/4th-ras-targeted-drug-development-summit/
LOCATION:Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR